These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 9706122)
1. Prevention of type 2 diabetes. Goldberg RB Med Clin North Am; 1998 Jul; 82(4):805-21. PubMed ID: 9706122 [TBL] [Abstract][Full Text] [Related]
2. Type II diabetes mellitus. Edelman SV Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190 [TBL] [Abstract][Full Text] [Related]
3. [Glinide(s), sulfonylurea(s)]. Arakawa M; Hirose T Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304 [TBL] [Abstract][Full Text] [Related]
4. [Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus]. Asakura T; Ito Y Nihon Rinsho; 2005 Feb; 63 Suppl 2():237-41. PubMed ID: 15779378 [No Abstract] [Full Text] [Related]
5. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance. Lebovitz HE J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098 [TBL] [Abstract][Full Text] [Related]
6. Vascular disease and lipids in diabetes. Garber AJ Med Clin North Am; 1998 Jul; 82(4):931-48. PubMed ID: 9706127 [TBL] [Abstract][Full Text] [Related]
8. Novel Strategies for Inducing Glycemic Remission during the Honeymoon Phase of Type 2 Diabetes. Retnakaran R Can J Diabetes; 2015 Dec; 39 Suppl 5():S142-7. PubMed ID: 26653254 [TBL] [Abstract][Full Text] [Related]
9. Prevention of type 2 diabetes. McFarlane SI; Shin JJ; Rundek T; Bigger JT Curr Diab Rep; 2003 Jun; 3(3):235-41. PubMed ID: 12762972 [TBL] [Abstract][Full Text] [Related]
10. [Effects of nateglinide in impaired glucose tolerance subjects]. Hirose T Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419 [No Abstract] [Full Text] [Related]
11. [Characteristic of metformin for treatment of impaired glucose tolerance]. Ishida W; Satoh J Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418 [No Abstract] [Full Text] [Related]
12. Multifactorial aspects of the treatment of the type II diabetic patient. Colwell JA Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550 [TBL] [Abstract][Full Text] [Related]
13. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. Lamy A; Tong W; Jung H; Gafni A; Singh K; Tyrwhitt J; Yusuf S; Gerstein HC; J Diabetes Complications; 2014; 28(4):553-8. PubMed ID: 24684774 [TBL] [Abstract][Full Text] [Related]
14. Implications of the diabetes control and complications trial. American Diabetes Association. J Fla Med Assoc; 1998 Aug; 85(2):22-4. PubMed ID: 9782715 [No Abstract] [Full Text] [Related]
15. [Management of diabetes mellitus in patients with angiopathies]. Lohmann T Z Kardiol; 2005; 94 Suppl 4():IV/28-30. PubMed ID: 16416060 [TBL] [Abstract][Full Text] [Related]
16. [Microangiopathic complications in type 2 diabetes]. Strojek K; Grzeszczak W Wiad Lek; 1998; 51 Suppl 2():45-51. PubMed ID: 9686533 [TBL] [Abstract][Full Text] [Related]
17. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]. Nakamura J Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422 [No Abstract] [Full Text] [Related]